Terms: = Kidney tumors AND FLT4, FLT41, 2324, ENSG00000037280, P35916, VEGFR3, PCL AND Prognosis
12 results:
1. Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinoma.
Tamukong PK; Kuhlmann P; You S; Su S; Wang Y; Yoon S; Gong J; Figlin RA; Janes JL; Freedland SJ; Halabi S; Small EJ; Rini BI; Kim HL
Urol Oncol; 2022 Nov; 40(11):495.e1-495.e10. PubMed ID: 35973929
[TBL] [Abstract] [Full Text] [Related]
2. Tivozanib: A New Hope for Treating Renal Cell Carcinoma.
Passi I; Billowria K; Kumar B; Chawla PA
Anticancer Agents Med Chem; 2023; 23(5):562-570. PubMed ID: 35718972
[TBL] [Abstract] [Full Text] [Related]
3. Comparison of prognosis between patients undergoing radical nephrectomy versus partial nephrectomy for renal cell carcinoma ≤7 cm T3aN0/xM0: Survival benefit is biased toward partial nephrectomy.
Liu S; Feng C; Liu C; Wang Z
Cancer Med; 2021 Dec; 10(24):8909-8923. PubMed ID: 34779154
[TBL] [Abstract] [Full Text] [Related]
4. Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16).
Basso U; Procopio G; Fornarini G; Massari F; Bearz A; Fratino L; Milella M; Bassanelli M; Ermacora P; Bimbatti D; Verzoni E; Rizzo M; Porta C
Oncology; 2021; 99(12):747-755. PubMed ID: 34583356
[TBL] [Abstract] [Full Text] [Related]
5. The effect of serum uric acid levels on the long-term prognosis of patients with non-ST-elevation myocardial infarction.
Kuźma Ł; Kulikowska A; Kurasz A; Niwińska MM; Zalewska-Adamiec M; Dobrzycki S; Bachórzewska-Gajewska H
Adv Clin Exp Med; 2020 Nov; 29(11):1255-1263. PubMed ID: 33269811
[TBL] [Abstract] [Full Text] [Related]
6. VEGF receptor subtypes may serve as novel prognostic factors and putative indicators for anti VEGF receptor treatment response in renal cell carcinoma cases.
Eronat O; Onursever A; Suren D; Yildirim M; Kandemir O; Ali Kahya H
J BUON; 2016; 21(5):1250-1258. PubMed ID: 27837630
[TBL] [Abstract] [Full Text] [Related]
7. Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer.
Yuasa T; Takahashi S; Hatake K; Yonese J; Fukui I
Cancer Sci; 2011 Nov; 102(11):1949-57. PubMed ID: 21812860
[TBL] [Abstract] [Full Text] [Related]
8. [Expression of VEGFR-2 and VEGFR-3 in papillary renal cell carcinoma and their relationship with prognosis].
Zhang YH; Diao L; Yang Q; Duo J; Liu YX; Liu SX; Yao X
Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):752-6. PubMed ID: 21163065
[TBL] [Abstract] [Full Text] [Related]
9. Sustained response following sorafenib therapy in an older adult patient with advanced renal cancer on hemodialysis: a case report.
Castagneto B; Stevani I; Giorcelli L; Montefiore F; Bigatti GL; Pisacco P; Cosimi MF
Med Oncol; 2011 Dec; 28(4):1384-8. PubMed ID: 20552299
[TBL] [Abstract] [Full Text] [Related]
10. [Correlation between symptoms and survival in patients with renal cell carcinoma].
Ares Valdés Y
Arch Esp Urol; 2009 Apr; 62(3):201-6. PubMed ID: 19542592
[TBL] [Abstract] [Full Text] [Related]
11. Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma.
Klatte T; Pantuck AJ; Said JW; Seligson DB; Rao NP; LaRochelle JC; Shuch B; Zisman A; Kabbinavar FF; Belldegrun AS
Clin Cancer Res; 2009 Feb; 15(4):1162-9. PubMed ID: 19228721
[TBL] [Abstract] [Full Text] [Related]
12. Lymphangiogenesis in kidney cancer: expression of VEGF-C, VEGF-D and VEGFR-3 in clear cell and papillary renal cell carcinoma.
Bierer S; Herrmann E; Köpke T; Neumann J; Eltze E; Hertle L; Wülfing C
Oncol Rep; 2008 Oct; 20(4):721-5. PubMed ID: 18813809
[TBL] [Abstract] [Full Text] [Related]
